Treatment of Slow-Flow After Primary Percutaneous Coronary Intervention With Flow-Mediated Hyperemia: The Randomized RAIN-FLOW Study.
ST‐segment‐elevation myocardial infarction
absolute coronary blood flow
hyperemia
no reflow phenomenon
primary percutaneous coronary intervention
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
medline:
6
7
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Background ST-segment-elevation myocardial infarction complicated with no reflow after primary percutaneous coronary intervention is associated with adverse outcomes. Although several hyperemic drugs have been shown to improve the Thrombolysis in Myocardial Infarction flow, optimal treatment of no reflow remains unsettled. Saline infusion at 20 mL/min via a dedicated microcatheter causes (flow-mediated) hyperemia. The objective is to compare the efficacy of pharmacologic versus flow-mediated hyperemia in patients with ST-segment-elevation myocardial infarction complicated with no reflow. Methods and Results In the RAIN-FLOW (Treatment of Slow-Flow After Primary Percutaneous Coronary Intervention With Flow-Mediated Hyperemia) study, 67 patients with ST-segment-elevation myocardial infarction and no reflow were randomized to receive either pharmacologic-mediated hyperemia with intracoronary adenosine or nitroprusside (n=30) versus flow-mediated hyperemia (n=37). The angiographic corrected Thrombolysis in Myocardial Infarction frame count and the minimal microcirculatory resistance, as assessed with intracoronary pressure-thermistor wire, dedicated microcatheter, and thermodilution techniques, were compared after study interventions. Both Thrombolysis in Myocardial Infarction frame count(40.2±23.1 versus 39.2±20.7;
Identifiants
pubmed: 37345805
doi: 10.1161/JAHA.123.030285
pmc: PMC10356082
doi:
Banques de données
ClinicalTrials.gov
['NCT04685941']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e030285Références
Am J Cardiol. 2021 Feb 15;141:31-37
pubmed: 33220317
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Atherosclerosis. 2022 Jul;352:46-52
pubmed: 35667163
Circulation. 1996 Mar 1;93(5):879-88
pubmed: 8598078
J Am Coll Cardiol. 2015 Apr 14;65(14):1454-71
pubmed: 25857912
J Am Coll Cardiol. 2014 Nov 18-25;64(20):2101-8
pubmed: 25457398
Circ Cardiovasc Interv. 2017 Apr;10(4):
pubmed: 28400462
J Am Coll Cardiol. 2010 May 25;55(21):2383-9
pubmed: 20488311
JACC Cardiovasc Interv. 2017 Feb 13;10(3):215-223
pubmed: 28183461
Eur Heart J. 2017 Nov 01;38(41):3056-3065
pubmed: 29020314
Circulation. 2013 Jun 18;127(24):2436-41
pubmed: 23681066
Rev Esp Cardiol (Engl Ed). 2017 Mar;70(3):155-161
pubmed: 27600863
Int J Cardiol. 2021 Jun 15;333:1-7
pubmed: 33684380
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1):
pubmed: 28073848
Cardiovasc Revasc Med. 2016 Mar;17(2):81-7
pubmed: 26905054
Circulation. 2022 Jan 18;145(3):e4-e17
pubmed: 34882436
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1559-1571
pubmed: 29805111
Am J Cardiol. 2007 Apr 1;99(7):916-20
pubmed: 17398183